Genomtec S.A. is mainly involved in conducting research and development activities, as well as commercialization of its innovative molecular diagnostic products in the area of optical systems and isothermal nucleic acid amplification methods.

The company’s flagship project is Genomtec ID. Its creation and commeercialization will allow the diagnostic process to be executed in point of care setting, such as: primary care clinics, pharmacies, doctor’s offices, hospital emergency departments (ERs) without the need for complicated and time-consuming laboratory workflow conducted by qualified personnel. The main benefits of Genomtec ID are: small size of the analyzer, low energy consumption, shortened diagnostic time, wide spectrum and high accuracy of the analysis, as well as affordable price. All these features will put Genomtec ID ahead of other genetic diagnostic devices currently available on the global market.

Genomtec is also involved in the development and commercialization of laboratory tests for infectious diseases detection. The company thus meets the urgent need of fighting the COVID-19 pandemic caused by the SARS-CoV-2 virus.

The company’s ambition is to createa new standard for clinical genetic diagnostics using the Genomtec ID platform.Thanks to the mobility, speed and efficiency of the device that can help detect viruses, bacteria and fungi, as well as genetic mutations by analyzing the biological material of patients using swabs, urine samples, saliva, blood or other body fluids, it will be possible to implement appropriate treatment during one medical visit.

According to the Management Board of Genomtec SA,the flagship product will be commercialisedin the first halfof 2022.

The COVID-19 pandemic has shown that rapidly determining the pathogenesis, or causes of the disease, at the level of basic cellular structures (RNA and DNA) is the new expected standard. Genetic diagnostics already offers the highest level of efficiency and precision in detecting pathogens. Upcoming epidemic challenges, such as, for example, subsequent epidemic cycles, rising treatment costs, aging population or rise in occurance of of neoplastic diseases have pushed the bar in the development of diagnostic technologies. Speed, efficiency and cost-effectiveness – these are the features that products available on the medical screening and diagnostic market should have in the near future. These expectations are met by new technological solutions, i.e. devices that allow conducting point-of-care testing (POCT).

Since its beginnings in 2016, the Genomtec team knew that rapid genetic diagnosis is the future of the market. In addition, the company chose to work withthe new technology of Loop-Mediated Isothermal Nucleic Acid Amplification – LAMP..

It is an important part of the developed analyzer’s design based on the patentedSNAAT®technology, consisting of photon energy contactless heating and temperature detection embedded in the analyzer system, which together with the microfluidic card and firmware creats the Genomtec ID mobile genetic diagnostics platform.

Diagnostics Process with Genomtec SARS-Cov-2 EvaGreen Direct-RT-LAMP CE-IVD Kit - Video